<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893048</url>
  </required_header>
  <id_info>
    <org_study_id>8876</org_study_id>
    <nct_id>NCT00893048</nct_id>
  </id_info>
  <brief_title>The Use of Oral Steroids in the Treatment of Cellulitis</brief_title>
  <official_title>Utility of Prednisone in the Treatment of Cellulitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of cellulitis in society is very high, as much as 3% of visits to Emergency&#xD;
      Departments are for the treatment of this disease. The treatment of cellulitis varies&#xD;
      depending on the severity. Low severity cases are treated with pain control and antibiotics&#xD;
      by mouth and high severity are treated with antibiotics intravenously and pain control. The&#xD;
      investigator's hypothesis is to see if the addition of steroids, which are known to decrease&#xD;
      inflammation, will decrease the length of the disease process. If so, it will decrease the&#xD;
      length of stay if IV antibiotics are needed, it will decrease duration of days out of work&#xD;
      and decrease the overall pain control required and therefore patient satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of cellulitis is about 24.6 cases per 1000 person-years, which is an estimate,&#xD;
      since cellulitis is not a reportable disease. In some Emergency Departments up to 3% of&#xD;
      visits are for cellulitis. Depending on the severity of the disease, some are treated as&#xD;
      outpatients, and others are admitted for IV antibiotics. In some Emergency Departments cases&#xD;
      of cellulitis are treated in an observation area for 23 hours with doses of IV antibiotics.&#xD;
      My proposed research is to see if the addition of one dose of prednisone the treatment will&#xD;
      decrease the inflammatory reaction enough to decrease length of stay and treatment and&#xD;
      increase patient satisfaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never enrolled any subjects before auto-terminated by the internal IRB.&#xD;
  </why_stopped>
  <start_date type="Actual">January 15, 2010</start_date>
  <completion_date type="Actual">August 31, 2010</completion_date>
  <primary_completion_date type="Actual">August 31, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to cellulitis resolving</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>after treatment completed</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cellulitis</condition>
  <condition>Erysipelas</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of prednisone to decrease LOS and overall treatment time of cellulitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone, 60 mg, one time at time of diagnosis</description>
    <arm_group_label>Prednisone</arm_group_label>
    <other_name>sterapred</other_name>
    <other_name>sterapred DS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years old&#xD;
&#xD;
          -  signs/symptoms of cellulitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  steroid use in last 2 weeks&#xD;
&#xD;
          -  hx of adrenal insufficiency&#xD;
&#xD;
          -  suspicion for dvt or abcess&#xD;
&#xD;
          -  systemic signs of sepsis&#xD;
&#xD;
          -  ICU admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Goldstein, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State</affiliation>
  </overall_official>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prednisone</keyword>
  <keyword>cellulitis</keyword>
  <keyword>erysipelas</keyword>
  <keyword>steroids</keyword>
  <keyword>oral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulitis</mesh_term>
    <mesh_term>Erysipelas</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

